Navidea Biopharma (NAVB) Misses Q3 EPS by 1c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. WCN
6. SPOT
7. FIX
8. TSCO
9. BE
10. SLM

Go back to Navidea Biopharma (NAVB) Misses Q3 EPS by 1c

Navidea Reports 2015 Third Quarter Financial Results

November 4, 2015 7:30 AM EST

DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals (NYSE MKT: NAVB) reports financial results for the quarter ending September 30, 2015. The Company achieved the following financial highlights:

Third quarter 2015 total revenue of $4 million; comprised of $3 million in Lymphoseek® (technetium Tc 99m tilmanocept) injection sales, $550,000 in Lymphoseek license revenue, and $477,000 in grant and other revenue 50% sequential quarterly and 168% year-over-year third quarter Lymphoseek product sales growth Year-to-date gross margins on product sales of 82% $6.8 million in 2015 year-to-date product sales, which puts... More